Non-Hodgkin Lymphoma: Diagnosis, Treatment and Side Effect Management
Recorded on: July 15, 2024
Recorded on: July 15, 2024
Estimated Time to Complete: 1.5 hours
1.5 CE Credits/Contact hours for nurses and social workers available until: May 6, 2026
Format: Non-interactive recorded webinar
Target Audience
This activity is intended for oncology nurse practitioners, nurses, social workers, and other healthcare professionals involved in the care of patients with non-Hodgkin lymphoma.
Course content level for social workers: all levels
Description
This program covers the subtypes of NHL, advancements in diagnosis, approved and emerging treatment options, the role of clinical trials, goals of treatment, side effect management, and healthcare professional considerations when caring for these patients. The goal is to help participants gain knowledge of NHL’s complexities, and resources for educating and supporting patients, to foster improved patient outcomes.
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe the various types and subtypes of NHL
- Identify tests used to diagnose disease and monitor treatment
- Explain the overarching goals of treatment for the types of NHL
- Explain approved and emerging treatment options, including CAR T-cell therapy, and the role of clinical trials
- Describe strategies to manage treatment side effects as well as potential long-term and late effects of treatments
- Describe the healthcare professional’s role in managing patients with NHL
Faculty
Matt McKinney, MD
Assistant Professor of Medicine
Duke University School of Medicine
Durham, NC
Meredith T. Moorman, PharmD, BCOP, CPP
Clinical Pharmacist, Adult Outpatient
Leukemia & Lymphoma Clinic
Duke Blood Cancer Center
Durham, NC
Melissa Reinhold, RN, BSN, OCN
Oncology Nurse Navigator
Duke Blood Cancer Center
Durham, NC
Continuing Education Information
Nursing Continuing Professional Development
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.5 continuing education contact hours through the California Board of Registered Nursing.
Social Worker Continuing Education
The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved as an ACE provider to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Regulatory boards are the final authority on courses accepted for continuing education credit. ACE provider approval period: 12/10/2023-12/10/2026. Social workers completing this course receive 1.5 clinical continuing education credits.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program. Social workers will receive 1.5 clinical CE contact hours for this activity.
Nurse Practitioner Continuing Education
This education activity will be submitted to the American Association of Nurse Practitioners® for approval of up to 1.5 contact hours of accredited education.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity posttest, evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit.
If you have questions regarding your certificate, please contact Nicole Dane via email at ndane@kimeglobal.com.
Providers
This activity is provided by The Leukemia & Lymphoma Society.
Supporters
There is no commercial support associated with this CE activity.
Participants gain access to the webinar via the participation button above.
For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at ProfEducation@LLS.org.